Abstract OT1-2-01: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx)
MA Cobleigh(Northwestern University), Norman Wolmark(NSABP Foundation), Peiming Zheng(Chinese Academy of Sciences), EP Mamounas(Northwestern University), SJ Anderson(Northwestern University), TB Julian(Northwestern University), R Rabinovitch(Northwestern University), D.W. Arthur(Northwestern University), KP Siziopikou(Northwestern University)
Cited by 2
Related Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
|New England Journal of Medicine|2005|5.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells
|Journal of Experimental & Clinical Cancer Research|2017|656